August 15, 2014

Mallinckrodt announced that it has completed the acquisiton of Questcor Pharmaceuticals in a transaction valued at $5.8 billion.

April 7, 2014

Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.

March 20, 2014

Mallinckrodt, a specialty pharmaceuticals company, announced the completion of its acquisition of Cadence Pharmaceuticals for approximately $1.4 billion.

March 18, 2014

Mallinckrodt Plc last week announced that the Food and Drug Administration approved Xartemis XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), for the management of acute pain severe enough that it requires opioid treatment.

February 12, 2014

Mallinckrodt and Cadence Pharmaceuticals on Tuesday announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals for $14.00 per share in cash.

July 2, 2013

Covidien has finished spinning off its pharmaceuticals division, the medical products maker said.

April 26, 2013

Medical products manufacturer Covidien's pharmaceutical division is expanding an initiative to collect unused and unwanted medications.

January 27, 2012

Watson Pharmaceuticals and Mallinckrodt have reached a settlement concerning a painkiller for which the former had sought Food and Drug Administration approval.

February 11, 2011

The Food and Drug Administration has approved a painkiller delivered through a skin patch made by Mallinckrodt, the generic drug maker said Friday.

December 1, 2010

Specialty pharmacy provider BioScrip has appointed David Froesel as EVP, CFO and treasurer, the company said Wednesday. Froesel will begin immediately, replacing Stan Rosembaum, who plans to leave the company before the year ends.